Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia

European Neuropsychopharmacology

Volumn 22, Issue 11, 2012, Pages 812-817

  Levine, Stephen Z ^a   Leucht, Stefan ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Delayed response; Early response; Negative symptoms; Scale for the Assessment of Negative Symptoms; Treatment

Indexed keywords

AMISULPRIDE; PLACEBO;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG MECHANISM; EFFECT SIZE; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ANHEDONIA; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TIME FACTORS;

EID: 84867498593     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.03.001     Document Type: Article

References (16)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1235.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City.
3. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry 1995, 166:68-72.
4. Danion J.M., Rein W., Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiatry 1999, 156:610-616.
5. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32:250-258.
6. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
7. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 2005, 57:1543-1549.
8. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
9. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79:231-238.
10. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98:318-322.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
12. Loo H., Poirier-Littre M.F., Theron M., Rein W., Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry 1997, 170:18-22.
13. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 2001, 11:9-21.
14. Mallinckrodt C.H., Clark W.S., David S.R. Type I error rates from mixed effects model repeated measures versus fixed effects anova with missing values imputed via last observation carried forward. Drug Inf. J. 2001, 35:1215-1225.
15. Rabinowitz, J, Levine, S.Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C.G., Kapur, S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophr. Res., in press.
16. Storosum J.G., Elferink A.J., van Zwieten B.J., van Strik R., Hoogendijk W.J., Broekmans A.W. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?. Schizophr. Bull. 2002, 28:193-201.